Oct 7 (Reuters) - A drug compounding industry group on

Monday sued the U.S. Food and Drug Administration over its

decision to take Eli Lilly's ( LLY ) blockbuster weight loss and

diabetes drugs from its shortage list last week, a move expected

to curtail compounding facilities' ability to sell their own

versions of the drugs.

In a lawsuit in Fort Worth, Texas federal court, the

Outsourcing Facilities Association claims the FDA removed

tirzepatide from the list even though it remains in short

supply. Lilly sells the drug under the brand names Zepbound for

weight loss and Mounjaro for diabetes.